Skip to main content

TNF inhibitor

    Daily Recap: Day Three EULAR 2023
    RT @AurelieRheumo: Adherence to TNFi follows different trajectories

    Cluster 1: “moderate then high” 51%
    Cluster 2:
    10 months 1 week ago
    Adherence to TNFi follows different trajectories Cluster 1: “moderate then high” 51% Cluster 2: “moderate then low” 20% Cluster 3: “low adherence, to discontinuation” 18% Cluster 4: “low then high adherence” 11% Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
    RT @synovialjoints: The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients
    10 months 1 week ago
    The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
    RT @Janetbirdope: What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JA
    10 months 1 week ago
    What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD
    JAKpot or JAKnot
    Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today. Rheumatoid Factor Lowering Predicts Improved Outcomes in RA. Abstract…
    Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https:/
    10 months 1 week ago
    Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
    Daily Recap: Day One + Two
    RT @synovialjoints: JAKi use did not increase CV risk compared to TNF, no difference between Bari and Tofa, non signific
    10 months 1 week ago
    JAKi use did not increase CV risk compared to TNF, no difference between Bari and Tofa, non significant increased IRR in patients >65 years, Merel Opdam, Abst#OP0221 #EULAR2023 @RheumNow https://t.co/Pu5X8RHJOY